Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma

NCT02605356 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study restarted under new study number 18987

Conditions

Multiple Myeloma

Interventions

DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)
DRUG: Placebo
DRUG: Bortezomib
DRUG: Dexamethasone

Sponsor

Bayer